Phathom Pharmaceuticals (PHAT) Other Accumulated Expenses (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has 8 years of Other Accumulated Expenses data on file, last reported at $5.6 million in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $5.6 million, up 99.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.6 million (up 99.5% YoY), and the FY2025 annual result was $7.5 million, up 146.39% from the prior year.
• Other Accumulated Expenses fell to $5.6 million in Q1 2026 per PHAT's latest filing, from $7.5 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $7.5 million in Q4 2025 and troughed at $20000.0 in Q3 2023.
• A 5-year average of $1.9 million and a median of $726000.0 in 2024 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses slumped 46.15% in 2023, then jumped 8865.0% in 2024.
• A 5-year view of Other Accumulated Expenses shows it stood at $151000.0 in 2022, then dropped by 22.52% to $117000.0 in 2023, then soared by 2501.71% to $3.0 million in 2024, then surged by 146.39% to $7.5 million in 2025, then dropped by 25.17% to $5.6 million in 2026.
• Business Quant data shows PHAT's Other Accumulated Expenses at $5.6 million in Q1 2026, $7.5 million in Q4 2025, and $4.8 million in Q3 2025.